TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30063148

Group type: EXPERIMENTAL
Intervention: Horizontal scrub technique
Number of subjects: 163

Group type: COMPARATOR
Intervention: Fones technique
Number of subjects: 163
Study: 26906526

Group type: EXPERIMENTAL
Intervention: Anamorelin 100 mg orally once daily
Number of subjects: 979

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 979
Study: 25355194

Group type: EXPERIMENTAL
Intervention: Etoricoxib 60 mg once daily
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Paracetamol/acetaminophen 500 mg thrice daily
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo (empty capsules)
Number of subjects: 45
Study: 22762072

Group type: EXPERIMENTAL
Intervention: Female GPs
Number of subjects: 4467

Group type: EXPERIMENTAL
Intervention: Time, caring, involving the patient in decisions, putting the patient at ease, language, lower education, age >25 years, current fear
Number of subjects: 4467
Study: 20158920

Group type: EXPERIMENTAL
Intervention: Aerobic-based exercise training (6 months, thrice-weekly)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 70
Study: 18815543

Group type: EXPERIMENTAL
Intervention: Octreotide
Number of subjects: 2621

Group type: COMPARATOR
Intervention: Placebo (Control)
Number of subjects: 2621

Group type: EXPERIMENTAL
Intervention: Octreotide (in large-scale trials >200 cases)
Number of subjects: 2621
Study: 16637745

Group type: EXPERIMENTAL
Intervention: Participants who held a pen in their mouths to inhibit imitation of the faces.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control participants who could imitate freely.
Number of subjects: 0
Study: 11266148

Group type: EXPERIMENTAL
Intervention: Comprehensive, 18-month life-style intervention program
Number of subjects: 128

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 128
Study: 9895267

Group type: EXPERIMENTAL
Intervention: Transurethral electrovaporization of the prostate (TVP)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Transurethral resection of the prostate (TURP)
Number of subjects: 76
Study: 7994169

Group type: EXPERIMENTAL
Intervention: Autonomic failure patients
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Patients with severe autonomic failure and orthostatic hypotension
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 25
Study: 2500169

Group type: EXPERIMENTAL
Intervention: Metoprolol 100 mg twice daily for 16 weeks
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Atenolol 25 mg twice daily for 16 weeks
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo (run-in period of 4-6 weeks)
Number of subjects: 60
Study: 815189

Group type: EXPERIMENTAL
Intervention: Indomethacin (50 mg, three times a day for 2 days)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Indomethacin
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 31884074

Group type: EXPERIMENTAL
Intervention: Circulating level of IGF1
Number of subjects: 397380

Group type: EXPERIMENTAL
Intervention: Genetic factors predicting IGF1 level
Number of subjects: 397380

Group type: EXPERIMENTAL
Intervention: Genetic factors predicting IGFBP3 level
Number of subjects: 397380
Study: 29652761

Group type: EXPERIMENTAL
Intervention: Inspiratory Muscle Training (IMT)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control (breathing training only)
Number of subjects: 38
Study: 27039022

Group type: EXPERIMENTAL
Intervention: Ranibizumab 0.5 mg
Number of subjects: 455

Group type: EXPERIMENTAL
Intervention: Ranibizumab 0.5 mg with laser
Number of subjects: 455

Group type: COMPARATOR
Intervention: Laser only
Number of subjects: 455
Study: 25198813

Group type: EXPERIMENTAL
Intervention: Power‐injectable PICCs with Solo‐2 proximal valve (Bard)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Power‐injectable PICCs with PASV proximal valve (Navilyst)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Non‐valved power‐injectable PICCs (Medcomp)
Number of subjects: 180
Study: 22316641

Group type: EXPERIMENTAL
Intervention: Low-carbohydrate diet
Number of subjects: 46

Group type: COMPARATOR
Intervention: Low-fat diet
Number of subjects: 46
Study: 20211020

Group type: EXPERIMENTAL
Intervention: Serum SP-D
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: SP-D during follow-up
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: SP-D in synovial fluid
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Baseline SP-D
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Temporal changes in SP-D
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: SP-D
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: SP-D genotype
Number of subjects: 160
Study: 18817809

Group type: EXPERIMENTAL
Intervention: P1 (intensive relaxation response training)
Number of subjects: 225

Group type: COMPARATOR
Intervention: P2 (group program without relaxation response training)
Number of subjects: 225

Group type: COMPARATOR
Intervention: P3 (self-guided mail-delivered program)
Number of subjects: 225
Study: 16277666

Group type: EXPERIMENTAL
Intervention: Acetaminophen
Number of subjects: 235

Group type: EXPERIMENTAL
Intervention: Regular exercise
Number of subjects: 235

Group type: EXPERIMENTAL
Intervention: Prayer
Number of subjects: 235

Group type: EXPERIMENTAL
Intervention: Heat and cold
Number of subjects: 235

Group type: EXPERIMENTAL
Intervention: Opioids
Number of subjects: 235

Group type: EXPERIMENTAL
Intervention: Nonsteroidal anti-inflammatory drugs
Number of subjects: 235
Study: 12861112

Group type: EXPERIMENTAL
Intervention: PureVision lens (silicone hydrogel)
Number of subjects: 13

Group type: COMPARATOR
Intervention: ACUVUE 2 lens (conventional hydrogel)
Number of subjects: 13
Study: 10206132

Group type: EXPERIMENTAL
Intervention: Early dexamethasone treatment (from day 7)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Late dexamethasone treatment (from day 14)
Number of subjects: 30
Study: 7774174

Group type: EXPERIMENTAL
Intervention: Dental sealants combined with ongoing school-based fluoride program
Number of subjects: 416

Group type: COMPARATOR
Intervention: Fluoride therapy only (control group)
Number of subjects: 416

Group type: EXPERIMENTAL
Intervention: Dental sealants
Number of subjects: 416
Study: 2078794

Group type: EXPERIMENTAL
Intervention: Combined modality therapy (radiation in combination with 5-FU)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Surgery alone (control group)
Number of subjects: 0
Study: 78527

Group type: EXPERIMENTAL
Intervention: Dioctyl calcium sulfosuccinate (DCS) (Surfak), q.d.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Dioctyl sodium sulfosuccinate (DSS) (Colace), q.d. and b.i.d.
Number of subjects: 0
Study: 31828874

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided refills
Number of subjects: 107

Group type: COMPARATOR
Intervention: Template-guided refills
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Patient preference after ultrasound-guided refills
Number of subjects: 107
Study: 30171362

Group type: EXPERIMENTAL
Intervention: PFC Sigma RP‐F mobile model
Number of subjects: 110

Group type: COMPARATOR
Intervention: PFC Sigma PS fixed model
Number of subjects: 110
Study: 27502852

Group type: EXPERIMENTAL
Intervention: Prasugrel
Number of subjects: 7243

Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 7243
Study: 24035556

Group type: EXPERIMENTAL
Intervention: Web-based videoconferencing (eGetgoing)
Number of subjects: 85

Group type: COMPARATOR
Intervention: In-person counseling
Number of subjects: 85
Study: 22331521

Group type: EXPERIMENTAL
Intervention: Hibiscus sabdariffa L. aqueous extract (HSE)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Water (control)
Number of subjects: 8
Study: 20089827

Group type: EXPERIMENTAL
Intervention: Moxifloxacin 400 mg/d for 1 week
Number of subjects: 22

Group type: COMPARATOR
Intervention: Cyclosporine
Number of subjects: 22

Group type: COMPARATOR
Intervention: Tacrolimus
Number of subjects: 22
Study: 16900082

Group type: EXPERIMENTAL
Intervention: Vitamin B12 supplementation (1-18 microg/daily)
Number of subjects: 89

Group type: COMPARATOR
Intervention: Partly supplemented and not supplemented groups
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Total TC (holoTC)
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Total HC (holoHC)
Number of subjects: 89
Study: 15338103

Group type: EXPERIMENTAL
Intervention: Methylphenidate (30 mg single dose)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 12017408

Group type: EXPERIMENTAL
Intervention: Gemifloxacin 320 mg once daily for 5 days
Number of subjects: 712

Group type: COMPARATOR
Intervention: Clarithromycin 500 mg twice daily for 7 days
Number of subjects: 712

Group type: EXPERIMENTAL
Intervention: Gemifloxacin
Number of subjects: 712

Group type: COMPARATOR
Intervention: Clarithromycin
Number of subjects: 712
Study: 10850384

Group type: EXPERIMENTAL
Intervention: Consensus Interferon (CIFN), 9 microg, subcutaneous injection, three times weekly for 24 weeks
Number of subjects: 472

Group type: COMPARATOR
Intervention: Interferon alfa‐2b (IFN alfa‐2b), 3 MU, subcutaneous injection, three times weekly for 24 weeks
Number of subjects: 472

Group type: EXPERIMENTAL
Intervention: Serotype or genotype 2 or 3 (independently of treatment)
Number of subjects: 472
Study: 8565197

Group type: EXPERIMENTAL
Intervention: Sodium hyaluronate ophthalmic solution (0.1%)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Artificial tears (control)
Number of subjects: 43
Study: 1781800

Group type: EXPERIMENTAL
Intervention: Diclofenac plus sucralfate
Number of subjects: 24

Group type: COMPARATOR
Intervention: Diclofenac alone
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Piroxicam plus sucralfate
Number of subjects: 24

Group type: COMPARATOR
Intervention: Piroxicam alone
Number of subjects: 24
Study: 7020900

Group type: EXPERIMENTAL
Intervention: alpha-methyldopa (750 mg/d orally)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Combination of alpha-methyldopa and chlorothiazide
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 31549793

Group type: EXPERIMENTAL
Intervention: Abatacept plus MTX
Number of subjects: 225

Group type: COMPARATOR
Intervention: MTX
Number of subjects: 225
Study: 31690312

Group type: EXPERIMENTAL
Intervention: Omentopexy with Glubran®2
Number of subjects: 186

Group type: COMPARATOR
Intervention: Control group (no omentopexy with Glubran®2)
Number of subjects: 186
Study: 28248896

Group type: EXPERIMENTAL
Intervention: Chewing gum
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study: 25060413

Group type: EXPERIMENTAL
Intervention: Alirocumab 150 mg every 2 weeks (Q2W)
Number of subjects: 176

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 176
Study: 22544511

Group type: EXPERIMENTAL
Intervention: Skin cancer education video in American Sign Language (n=75)
Number of subjects: 136

Group type: COMPARATOR
Intervention: Alternate video (n=61)
Number of subjects: 136

Group type: COMPARATOR
Intervention: Delayed intervention group (original control group)
Number of subjects: 136
Study: 19533165

Group type: EXPERIMENTAL
Intervention: Citalopram (CITAL 2 x 10 mg)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo (PLA: lactose 2 x 10 mg)
Number of subjects: 11
Study: 17207172

Group type: EXPERIMENTAL
Intervention: EGF (10 microg/g) in 0.1% silver sulfadiazine cream
Number of subjects: 20

Group type: COMPARATOR
Intervention: 0.1% silver sulfadiazine cream alone
Number of subjects: 20
Study: 15862200

Group type: EXPERIMENTAL
Intervention: Magnetoencephalography (MEG) measuring gamma oscillations (30-70 Hz) in human visual cortex
Number of subjects: 0

Group type: COMPARATOR
Intervention: Invasive measures of activation in primate visual cortex
Number of subjects: 0
Study: 12075760

Group type: EXPERIMENTAL
Intervention: AZM 10 mg/kg/day
Number of subjects: 501

Group type: EXPERIMENTAL
Intervention: AZM 20 mg/kg/day
Number of subjects: 501

Group type: COMPARATOR
Intervention: Penicillin V
Number of subjects: 501
Study: 9793623

Group type: COMPARATOR
Intervention: Klimonorm (Test preparation)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Reference preparation
Number of subjects: 32

Group type: COMPARATOR
Intervention: Klimonorm (Test preparation) and Reference preparation
Number of subjects: 32
Study: 7910865

Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 2231
Study: 2941493

Group type: EXPERIMENTAL
Intervention: Recombinant alpha-2 interferon (rIFN-alpha 2) at a dosage of 2 X 10(6) units, administered three times per week for one year
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Recombinant alpha-2 interferon (rIFN-alpha 2)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Recombinant alpha-2 interferon (rIFN-alpha 2) and Placebo
Number of subjects: 0
Study: 29843276

Group type: EXPERIMENTAL
Intervention: Robot-assisted training using Armeo Spring
Number of subjects: 34

Group type: COMPARATOR
Intervention: Conventional therapy (Control Group)
Number of subjects: 34
Study: 26638130

Group type: EXPERIMENTAL
Intervention: Paracetamol 1 g four times a day for 5 days
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Paracetamol
Number of subjects: 80
Study: 23886272

Group type: EXPERIMENTAL
Intervention: Coenzyme Q10 (CoQ10) treatment in FM patients
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 21481958

Group type: EXPERIMENTAL
Intervention: Levosimendan (0.3 mg/kg/min, administered weekly for 6h over 6 months)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Dobutamine (10 mg/kg/min, administered weekly for 6h over 6 months)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Dobutamine (10 mg/kg/min) + Levosimendan (0.2 mg/kg/min, administered weekly for 6h over 6 months)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Levosimendan
Number of subjects: 63
Study: 20670240

Group type: EXPERIMENTAL
Intervention: Lignocaine stained with methylene blue
Number of subjects: 63
Study: 17346378

Group type: EXPERIMENTAL
Intervention: Personal construct psychotherapy
Number of subjects: 64

Group type: COMPARATOR
Intervention: Normal clinical practice
Number of subjects: 64
Study: 15764270

Group type: EXPERIMENTAL
Intervention: Quality of Life (QOL) assessment using EORTC QLQ-C30 questionnaire
Number of subjects: 917

Group type: EXPERIMENTAL
Intervention: Pain and fatigue assessment
Number of subjects: 917

Group type: EXPERIMENTAL
Intervention: Demographic and disease-related factors analysis
Number of subjects: 917

Group type: EXPERIMENTAL
Intervention: Comparison of QOL scores
Number of subjects: 917
Study: 12032012

Group type: EXPERIMENTAL
Intervention: Lidocaine iontophoresis
Number of subjects: 26

Group type: COMPARATOR
Intervention: EMLA
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: No preference
Number of subjects: 26
Study: 9521970

Group type: EXPERIMENTAL
Intervention: Letter followed by automated telephone message
Number of subjects: 648

Group type: COMPARATOR
Intervention: Letter alone
Number of subjects: 648

Group type: COMPARATOR
Intervention: Automated telephone message alone
Number of subjects: 648

Group type: EXPERIMENTAL
Intervention: Telephone message followed by letter
Number of subjects: 648

Group type: COMPARATOR
Intervention: No systematic intervention (comparison group)
Number of subjects: 648
Study: 7743760

Group type: EXPERIMENTAL
Intervention: Human insulin
Number of subjects: 40

Group type: COMPARATOR
Intervention: Porcine insulin
Number of subjects: 40
Study: 2404837

Group type: EXPERIMENTAL
Intervention: Crossover to the other platinum compound (carboplatin if initially treated with cisplatin, and vice versa)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Rechallenged with the same drug (cisplatin or carboplatin)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Responders (both crossover and rechallenged)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Patients who relapsed before 18 months
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Patients who relapsed after 18 months
Number of subjects: 54
Study: 7304657

Group type: EXPERIMENTAL
Intervention: Single-dose cefaclor (2 g orally)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Multidose cefaclor (250 mg orally three times a day for 10 days)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Single-dose cefaclor (2 g orally) with ACB test (less inclusive criteria)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Multidose cefaclor (250 mg orally three times a day for 10 days) with ACB test (less inclusive criteria)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: ACB test (less inclusive criteria)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: ACB test (more inclusive criteria)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: CRP test
Number of subjects: 52
Study: 30445272

Group type: EXPERIMENTAL
Intervention: MMT CARE intervention (provider capacity building, group sessions, individual sessions)
Number of subjects: 2448

Group type: COMPARATOR
Intervention: Control condition (standard care)
Number of subjects: 2448

Group type: EXPERIMENTAL
Intervention: MMT CARE intervention (provider capacity building, individual sessions)
Number of subjects: 2448

Group type: EXPERIMENTAL
Intervention: MMT CARE intervention (individual sessions within first six months)
Number of subjects: 2448
Study: 28780479

Group type: EXPERIMENTAL
Intervention: Androgen deprivation therapy (ADT) + docetaxel (D)
Number of subjects: 385

Group type: COMPARATOR
Intervention: Androgen deprivation therapy (ADT) alone
Number of subjects: 385
Study: 25496917

Group type: EXPERIMENTAL
Intervention: DHEA (50 mg/day)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 99
Study: 24041373

Group type: EXPERIMENTAL
Intervention: Centralized pesticide storage facility
Number of subjects: 4446

Group type: EXPERIMENTAL
Intervention: Focus group discussions
Number of subjects: 4446
Study: 21857013

Group type: EXPERIMENTAL
Intervention: Postoperative visit by the same anaesthetist (Group 1)
Number of subjects: 3

Group type: COMPARATOR
Intervention: Postoperative visit by a nurse anaesthetist (Group 2)
Number of subjects: 3

Group type: COMPARATOR
Intervention: No visit (Group 3)
Number of subjects: 3
Study: 20191714

Group type: EXPERIMENTAL
Intervention: Music intervention during laceration repair
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Father present during procedure
Number of subjects: 57

Group type: COMPARATOR
Intervention: Control group (no music)
Number of subjects: 57
Study: 17223870

Group type: EXPERIMENTAL
Intervention: Topical methyl aminolaevulinate (MAL) cream (160 mg g(‐1)) applied for 3 hours
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo cream applied for 3 hours
Number of subjects: 16
Study: 15160686

Group type: EXPERIMENTAL
Intervention: Home health intervention consisting of an evidence-based nursing protocol, patient self-care guide, and training to improve nurses' teaching and support skills
Number of subjects: 371

Group type: EXPERIMENTAL
Intervention: Home health intervention
Number of subjects: 371
Study: 11282425

Group type: EXPERIMENTAL
Intervention: Fluorescence bronchoscopy (LIFE group)
Number of subjects: 64

Group type: COMPARATOR
Intervention: White light bronchoscopy (Control group)
Number of subjects: 64
Study: 9621830

Group type: EXPERIMENTAL
Intervention: Prior encoding of a word through visual perception (reading aloud)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prior encoding of a word through a task providing no direct visual experience (generation from a semantic cue)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Successful identification of target words
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Subjective estimates of the proportion of targets previously studied
Number of subjects: 0
Study: 7610529

Group type: EXPERIMENTAL
Intervention: Doxycyclin 2 x 100 mg p. o. for at least 14 days or Cefuroxim 2 x 500 mg if contraindicated
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ceftriaxon 1 x 2‐‐2 x 2 g i. v. or Cefotaxim 3 x 2 g i. v. for at least 14 days
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Corticosteroids in defined cases (pain syndrome)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Untreated patient groups
Number of subjects: 0
Study: 2782043

Group type: EXPERIMENTAL
Intervention: L-dopa 100 mg plus benserazide 25 mg
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 959118

Group type: EXPERIMENTAL
Intervention: Killed influenza vaccine given by injection
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Selective vaccination for high-risk groups (e.g., elderly, key workers)
Number of subjects: 0
Study: 31308276

Group type: EXPERIMENTAL
Intervention: Dentifrice containing 8% arginine and calcium carbonate (Group A)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Diode laser (810 nm) irradiation (Group B)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Combined use of dentifrice and diode laser (Group C)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Untreated control (Group D)
Number of subjects: 40
Study: 27868372

Group type: EXPERIMENTAL
Intervention: Liraglutide 1.2 mg once daily
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 26065919

Group type: EXPERIMENTAL
Intervention: P2-VP8 vaccine (10, 30, or 60 μg)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: P2-VP8 vaccine (60 μg)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: P2-VP8 vaccine (any dose)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 22924571

Group type: EXPERIMENTAL
Intervention: GH (dose based on IGF-I titration algorithm; n = 114)
Number of subjects: 151

Group type: COMPARATOR
Intervention: Observation (n = 37)
Number of subjects: 151
Study: 21422084

Group type: EXPERIMENTAL
Intervention: IVIg (0.75 g/kg)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo (5% glucose)
Number of subjects: 80
Study: 19527189

Group type: EXPERIMENTAL
Intervention: Local oestrogen therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Drugs enhancing nitric oxide or vasoactive intestinal polypeptide
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Phosphodiesterase inhibitors
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Local administration of dihydroepiandrosterone
Number of subjects: 0
Study: 17241419

Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A (BT‐A) 50 U
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study: 14722892

Group type: EXPERIMENTAL
Intervention: Lopinavir/ritonavir 800/200 mg once daily
Number of subjects: 38

Group type: COMPARATOR
Intervention: Lopinavir/ritonavir 400/100 mg twice daily
Number of subjects: 38